Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 5/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | SRD5A1 | P18405 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.47 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.47 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.47 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.47 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.46 |
| ▸ | BAD | Q92934 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
| ▸ | TDP2 | O95551 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31456551 | 0.89 | SRD5A2 (0.81) | SRD5A2MAPTNPC1RAB9ASRD5A1 | |
| SCHEMBL27506 | 0.89 | SRD5A2 (0.81) | SRD5A2MAPTNPC1RAB9ASRD5A1 | |
| SCHEMBL11812488 | 0.87 | NPC1 (0.56) | SRD5A2MAPTNPC1RAB9ASRD5A1 | |
| Hydrochloric Acid SCHEMBL9789481 | 0.87 | SRD5A2 (0.79) | SRD5A2MAPTNPC1RAB9ASRD5A1 | |
| SCHEMBL24503134 | 0.85 | SRD5A2 (0.49) | SRD5A2MAPTNPC1RAB9ASRD5A1 | |
| SCHEMBL1647589 | 0.83 | SRD5A2 (0.79) | SRD5A2MAPTNPC1RAB9ASRD5A1 | |
| SCHEMBL30976964 | 0.83 | SRD5A2 (0.79) | SRD5A2MAPTNPC1RAB9ASRD5A1 | |
| SCHEMBL11685606 | 0.81 | MAPK14 (0.60) | SRD5A2SRD5A1ALDH1A1MAPK14TTR | |
| SCHEMBL23166496 | 0.80 | MAPT (0.53) | SRD5A2MAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL577480 | 0.80 | PGR (0.49) | MAPTNPC1RAB9ASRD5A1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240269293-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | OD THERAPEUTICS LIMITED (CN) | 2024-08-15 | — | — | US | disclosed |
| EP-4313154-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | OD Therapeutics Limited (HK) | 2024-02-07 | — | — | EP | disclosed |
| CN-117355337-A | Protein-macromolecule conjugates and methods of use thereof | 奥迪曼药业科技有限公司 | 2024-01-05 | — | — | CN | disclosed |
| US-20220401561-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | AJ SCIENCES (YIXING) CO., LTD (CN) | 2022-12-22 | — | — | US | disclosed |
| US-20220401561-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | AJ SCIENCES (YIXING) CO., LTD (CN) | 2022-12-22 | — | — | US | disclosed |
| WO-2022212362-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2022-10-06 | — | — | WO | disclosed |
| EP-4037715-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | Beijing Xuanyi Pharmasciences Co., Ltd. (CN) | 2022-08-10 | — | — | EP | disclosed |
| CN-114630818-A | Protein-macromolecule conjugates and methods of use thereof | 北京轩义医药科技有限公司 | 2022-06-14 | — | — | CN | disclosed |
| WO-2021067458-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2021-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240269293-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | CD44, MACROD1, MSN | SRD5A2 4748/4885MAPT 1112/4885NPC1 3707/4885 |
| US-20220401561-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | CD44, SSB, DNPEP | SRD5A2 4699/4885MAPT 1431/4885NPC1 3854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.